

# Case Study

## AOA Diagnostics



*CIF Investment: November 2021*

**Imagine an annual blood test for women to screen for ovarian cancer, similar to the annual PSA test for early detection of prostate cancer.**

AOA is a **woman-led** diagnostics company working to **identify ovarian cancer early** in women with non-specific symptoms. AOA is developing **AkrivisGD**, a non-invasive liquid-biopsy blood test targeting tumor glycolipids as biomarkers for all stages of ovarian cancer. (AOA is also working on potential diagnostics and therapeutics for melanoma, as well as pan-cancer screening.)

**80%**  
*of ovarian cancer cases are diagnosed too late for treatment.*

*Ovarian cancer is the 5th leading cause of death for women worldwide.*

*A tool for accurate early diagnosis could save the lives of 100,000 women per year by 2035.*

### Milestones, Results and Recognition

- **AKRIVIS GD Correctly identified >90% ovarian cancers:** In early-stage samples
- **Inc Magazine: Top 100 Female Founders :** AOA's Oriana Papin-Zogbhi and Anna Milik Jeter were honored to be included on this list - 2022
- **Clinical Trial Enrollment:** 142 patients enrolled in the OVERT trial across 20 sites
- **Bloomberg New Economy 2023 Catalyst List:** CEO, Oriana Papin-Zogbhi, selected as one of Bloomberg's twenty global catalysts - 2023
- **Over-subscribed Seed Round of \$17.25 Million** - Closed November, 2023

### Pathway to Commercialization

Solution	Discovery	Research	Clinical Trials	Commercialization
AkrivisGD <i>Ovarian Cancer Diagnostic</i>	✓	✓	<i>In Progress</i>	